Ivan Timofeev

Ivan Timofeev

Auto-generated profile, based on publicly available information

Ivan Timofeev

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
CDClaire Dahyot-Fizelier
Claire Dahyot-Fizelier
ITIvan Timofeev
Ivan Timofeev
SMSandrine Marchand
Sandrine Marchand
PHPeter John Ashton Hutchinson
Peter John Ashton Hutchinson
BDBertrand Debaene
Bertrand Debaene
WCWilliam Couet
William Couet
Concentrations of unbound meropenem in the cerebral extracellular fluid (ECF) of two patients with acute brain injury were assessed by microdialysis. Brain ECF unbound-meropenem concentrations were lower than serum unbound-meropenem concentrations, with brain-to-serum area under the concentration-time curve ratios of 0.73 and 0.14. A pharmacokinetic model was developed to fit the experimental data adequately.

20 October 2014 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
RSRichard J. Shannon
Richard J. Shannon
ITIvan Timofeev
Ivan Timofeev
JNJürgens Nortje
Jürgens Nortje
PHPeter John Ashton Hutchinson
Peter John Ashton Hutchinson
KCKeri L. H. Carpenter
Keri L. H. Carpenter
Aims: The aims were to determine blood–brain barrier penetration and brain extracellular pharmacokinetics for the anticonvulsant vigabatrin (VGB; γ‐vinyl‐γ‐aminobutyric acid) in brain extracellular fluid and plasma from severe traumatic brain injury (TBI) patients, and to measure the response of γ‐aminobutyric acid (GABA) concentration in brain extracellular fluid.Methods: Severe TBI patients (n= 10) received VGB (0.5 g enterally, every 12 h). Each patient had a cerebral microdialysis catheter; two patients had a second catheter in a different region of the brain. Plasma samples were collected 0.5 h before and 2, 4 and 11.5 h after the first VGB dose. Cerebral microdialysis commenced before the first VGB dose and continued through at least three doses of VGB. Controls were seven severe TBI patients with microdialysis, without VGB.Results: After the first VGB dose, the maximum concentration of VGB (Cmax) was 31.7 (26.9–42.6) μmol l−1(median and interquartile range for eight patients) in plasma and 2.41 (2.03–5.94) μmol l−1in brain microdialysates (nine patients, 11 catheters), without significant plasma–brain correlation. After three doses, medianCmaxin microdialysates increased to 5.22 (4.24–7.14) μmol l−1(eight patients, 10 catheters). Microdialysate VGB concentrations were higher close to focal lesions than in distant sites. Microdialysate GABA concentrations increased modestly in some of the patients after VGB administration.Conclusions: Vigabatrin, given enterally to severeTBIpatients, crosses the blood–brain barrier into the brain extracellular fluid, where it accumulates with multiple dosing. Pharmacokinetics suggest delayed uptake from the blood.

17 April 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
MWMingze Wang
Mingze Wang
RLReidar Lystad
Reidar Lystad
HMHarry Mee
Harry Mee
ACAna M Castaño-Leon
Ana M Castaño-Leon
ITIvan Timofeev
Ivan Timofeev
AKAngelos Kolias
Angelos Kolias
Background: Core outcome sets (COSs) are important and necessary as they help standardize reporting in research studies. Cranioplasty following traumatic brain injury (TBI) or stroke is becoming increasingly common, leading to an ever-growing clinical and research interest, especially regarding the optimal material, cost-effectiveness, and timing of cranioplasty concerning neurological recovery and complications. Consequently, heterogeneous reporting of outcomes from such diverse studies has led to limited meta-analysis ability and an ongoing risk of outcome reporting bias. This study aims to define a standardized COS for reporting in all future TBI and stroke cranioplasty studies. Objective: This study has four aims: (1) undertake a systematic review to collate the most current outcome measures used within the cranioplasty literature; (2) undertake a qualitative study to understand better the views of clinicians, patients' relatives, and allied health professionals regarding clinical outcomes following cranioplasty; (3) undertake a Delphi survey as part of the process of gaining consensus for the COS; and (4) finalize consensus through a consensus meeting resulting in the COS. Methods: An international steering committee has been formed to guide the development of the COS. In addition, recommendations from other clinical initiatives such as COMET (Core Outcomes and Effectiveness Trials) and OMERACT (Outcome Measures in Rheumatology) have been adhered to. Phase 1 is data collection through a systematic review and qualitative study. Phase 2 is the COS development through a Delphi survey and consensus meetings with consensus definitions decided and agreed upon before the Delphi survey begins to avoid bias. Results: Phase 1 started at the end of 2019, following ethical approval in December 2019, and the project completion date is planned for the end of 2022 or beginning of 2023. Conclusions: This study should result in a consensus on a COS for cranioplasty, following TBI or stroke, to help standardize outcome reporting for future studies, which can be applied to future research and clinical services, help align future studies, build an increased understanding of cranioplasty and its impact on a patient’s function and recovery, and help standardize the evidence base. International Registered Report Identifier (IRRID): DERR1-10.2196/37442

1 September 2007 in British Journal of Neuroscience Nursing
Verified
Journal Article
Closed access
ECElizabeth Corteen
Elizabeth Corteen
ITIvan Timofeev
Ivan Timofeev
PKPeter Kirkpatrick
Peter Kirkpatrick
PHPeter John Ashton Hutchinson
Peter John Ashton Hutchinson

13 April 2026 in Critical Care
Verified
Journal Article
Open access
PDF file
AHAdel Helmy
Adel Helmy
MBMichael S. Baker
Michael S. Baker
PCPatrick M. Chen
Patrick M. Chen
AQAoife Quinn
Aoife Quinn
IJIbrahim Jalloh
Ibrahim Jalloh
PHPeter John Ashton Hutchinson
Peter John Ashton Hutchinson
Purpose: Secondary brain injury is a common cause of poor outcome after trauma, subarachnoid hemorrhage, and intracerebral hemorrhage, and optimizing treatment requires real-time insight into cerebral metabolism. Cerebral microdialysis (CMD) uniquely provides key related information, yet consensus on its use has not been updated since publication of the consensus statement from the 2014 International Microdialysis Forum. We aimed to assess expert consensus on the use of CMD in critical care and provide contemporary guidance to standardize practice and advance clinical implementation. Methods: We conducted a 3-round modified Delphi study with international experts in CMD and neurocritical care. Consensus was defined as ≥ 75% agreement among non-abstaining respondents, with a minimum of 30 non-abstaining respondents required per statement. Statements not reaching consensus were iteratively revised based on panelist feedback. Results: Forty of 67 invited experts (60%) from 9 countries participated. Sixty of 62 individual items achieved consensus (97%) across 9 domains: indications and patient selection, technical and procedural considerations, detecting deterioration and secondary injury, metabolic interpretation, treatment algorithms, glucose management, sampling frequency, core reporting items, and barriers to clinical implementation. Conclusion: This consensus statement provides updated, evidence-informed recommendations for the use of CMD in critical care. The panel reaffirmed many core recommendations from the 2014 consensus while making targeted advances: cautious extension of guidance to intracerebral hemorrhage, comprehensive reporting guidance addressing frequently omitted elements (19 items vs. 6 in 2014), and identification of 10 key barriers to routine clinical adoption.

26 August 2026 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
MBMichael S Baker
Michael S Baker
JHJoshua M Heihre
Joshua M Heihre
TKTomasz Kuliński
Tomasz Kuliński
CSClaudia A Smith
Claudia A Smith
BBBerfin Barlas
Berfin Barlas
AHAdel Helmy
Adel Helmy
Cerebral microdialysis (CMD) after traumatic brain injury (TBI) has focused on lactate/pyruvate ratio (LPR), overlooking lactate–pyruvate gradient (LPG, the linear regression slope within a time segment of CMD datapoints) as a proxy for anaerobic activity. We retrospectively applied changepoint detection to the linear lactate–pyruvate relationship (L = m P + b ) over time within patients from two independent CMD-monitored TBI cohorts (Cambridge, n = 510; Uppsala, n = 81), estimating per-segment LPG ( m ) and intercept ( b , capturing metabolic variance). In vitro, we tested whether rotenone-induced mitochondrial dysfunction increases LPG in hiPSC-derived neurons, as expected if LPG tracks anaerobic activity. In the Cambridge cohort, a median of two linear segments were identified per patient (median LPG = 19.83; median b = 0.54 mM). Between segments, LPR tracked LPG with heavy attenuation (β = 0.255). LPG was negatively associated with cerebral microdialysate glucose ( p < 0.001) and 6-month GOSE ( p = 0.039). Uppsala data confirmed pipeline robustness and replicated the LPG–glucose association ( p = 0.022). LPG was higher in rotenone-treated neurons than controls (32.9 vs 14.2, p < 0.001). LPG calculated per time segment provides a more accurate, outcome-associated proxy for anaerobic activity than datapoint-level LPR.